Rationale and design of a phase III randomised, double-blind, placebo-controlled, multicentre study evaluating the efficacy and safety of treatment with corticoSTeroids at onset, And Rituximab at relapse, of MOG-antibody-associated disease (STAR-MOG) Conference

Cotter, Isabella, Spelman, Tim, Kalincik, Tomas et al. (2025). Rationale and design of a phase III randomised, double-blind, placebo-controlled, multicentre study evaluating the efficacy and safety of treatment with corticoSTeroids at onset, And Rituximab at relapse, of MOG-antibody-associated disease (STAR-MOG) . Multiple Sclerosis, 31(3), 463-465.

International Collaboration

cited authors

  • Cotter, Isabella; Spelman, Tim; Kalincik, Tomas; Reddel, Stephen; Trewin, Benjamin; Lefelar, Julia; Ahmed, Sumaira; Barnett, Michael; Broadley, Simon; Brown, David; Butzkueven, Helmut; Fraser, Clare; Garber, Justin; George, Stacey; Hardy, Todd; Henderson, Andrew; Kermode, Allan; Klistorner, Alexander; Scott, Jeannette Lechner; McKay, Fiona; Miteff, Christina; Monif, Mastura; Pillai, Sekhar; Slee, Mark; van der Walt, Anneke; Kim, Ho Jin; Fujihara, Kazuo; Huda, Saif; Gastaldi, Matteo; Flanagan, Eoin; Geraldes, Ruth; Pittock, Sean; Marignier, Romain; Palace, Jacqueline; Lindley, Richard; Brilot, Fabienne; Dale, Russell; Ramanathan, Sudarshini

authors

date/time interval

  • September 24, 2025 -

publication date

  • September 1, 2025

published in

keywords

  • Clinical Neurology
  • Life Sciences & Biomedicine
  • Neurosciences
  • Neurosciences & Neurology
  • Science & Technology

Location

  • SPAIN, Barcelona

Conference

  • 41st Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)

publisher

  • SAGE PUBLICATIONS LTD

start page

  • 463

end page

  • 465

volume

  • 31

issue

  • 3